Video

Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis

Author(s):

Jason R. Gotlib

Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.

Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content
Patients with relapsed or refractory MDS may experience improved overall survival with , depending on certain prognostic factors.
November 20th 2024

Donor Lymphocyte Infusion May Improve Survival in R/R MDS

Ashley Chan
Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of woman with brown hair.
November 19th 2024

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

Spencer Feldman Darlene Dobkowski, MA
New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Image of a woman with short blonde hair, wearing a colorful striped shirt.
November 19th 2024

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

Alex Biese
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.
Image of red blood cells.
November 18th 2024

Trial for Patients With High-Risk MDS Misses Goal, Discontinues Study

Ashley Chan
A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.